Details for Patent: 9,616,096
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,616,096 protect, and when does it expire?
Patent 9,616,096 protects QBRELIS and is included in one NDA.
This patent has ten patent family members in eight countries.
Summary for Patent: 9,616,096
Title: | Lisinopril formulations |
Abstract: | Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction. |
Inventor(s): | Mosher; Gerold L. (Kansas City, MO), Miles; David W. (Kansas City, MO) |
Assignee: | SILVERGATE PHARMACEUTICALS, INC. (Greenwood Village, CO) |
Application Number: | 15/268,095 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,616,096 |
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 9,616,096
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF HYPERTENSION | See Plans and Pricing | ||||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | METHOD OF TREATING HYPERTENSION | See Plans and Pricing | ||||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF HEART FAILURE | See Plans and Pricing | ||||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF MYOCARDIAL INFARCTION | See Plans and Pricing | ||||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION | See Plans and Pricing | ||||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | ACUTE MYOCARDIAL INFARCTION | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,616,096
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 3003274 | See Plans and Pricing | |||
China | 108472252 | See Plans and Pricing | |||
China | 112972370 | See Plans and Pricing | |||
European Patent Office | 3368012 | See Plans and Pricing | |||
European Patent Office | 3960156 | See Plans and Pricing | |||
Spain | 2886869 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |